Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

C.M.S. Tesileanu, M.J. Van den Bent, M. Sanson, W. Wick, A.A. Brandes, P.M. Clement, S.C. Erridge, M.A. Vogelbaum, A.K. Nowak, J.F. Baurain, W.P. Mason, H. Wheeler, O.L. Chinot, S. Gill, M. Griffin, L. Rogers, W. Taal, R. Ruda, M. Weller, C. McBainM.E. Van Linde, T.S. Sabedot, Y. Hoogstrate, A. Von Deimling, I. De Heer, W.F.J. Van IJcken, R.W.W. Brouwer, K. Aldape, R.B. Jenkins, H.J. Dubbink, J.M. Kros, P. Wesseling, K.J. Cheung, V. Golfinopoulos, B.G. Baumert, T. Gorlia, H. Noushmehr, P.J. French*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)1547-1559
Number of pages13
JournalNeuro-oncology
Volume23
Issue number9
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • 1p/19q non-codeleted
  • anaplastic glioma
  • DNA methylation profiling
  • IDH mutant
  • patient prognostication
  • CENTRAL-NERVOUS-SYSTEM
  • GRADE
  • CLASSIFICATION
  • ASTROCYTOMAS
  • SURVIVAL
  • IDH1

Cite this